通过肠道微生物群调节mercaptopurine的肠道毒性和药理动力学
概括
默卡普托普林 (6-MP) 破坏肠道微生物群,恶化肠道损伤和白血病治疗中的毒性. 肠道微生物影响6-MP代谢和S-adenosylmethionine (SAM) 水平,这对药物的疗效和安全至关重要.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 默卡普托普林 (6-MP) 对于治疗儿科急性淋巴细胞白血病 (ALL) 是至关重要的.
- 肠道微生物群对6-MP代谢和毒性的作用仍然不太清楚.
- 了解这种相互作用是改善ALL治疗结果的关键.
研究的目的:
- 研究6-MP对肠道微生物群组成和功能的影响.
- 确定肠道微生物群的变化如何影响6-MP代谢和毒性.
- 探索微生物代谢物的作用,特别是S-adenosylmethionine (SAM),在6-MP的影响.
主要方法:
- 用6-MP.治疗小狗和小鼠.
- 分析肠道微生物群的组成和功能 (代谢学).
- 在假无细菌的老鼠和接受抗生素治疗的模型中进行的药理动力学研究.
主要成果:
- 6-MP显著改变了肠道微生物群,损害了SCFA生产和氨基酸合成.
- 微生物群的枯竭加剧了6-MP诱导的肠损伤和透性增加.
- 肠道微生物群的枯竭改变了6-MP甲基化代谢物和降低了血SAM水平,与*Alistipes*丰富度相关.
结论:
- 6-MP 破坏了肠道微生物群,这反过来加剧了药物诱导的肠道毒性.
- 由肠道微生物群衍生的SAM对于调节血SAM和6-MP甲基化至关重要.
- 准肠道微生物群可能提供一种策略,以减轻ALL患者的6-MP毒性.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
115
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
115
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
196
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
196
Factors Influencing Drug Absorption: Disease States and Pharmacology
491
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
491
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
244
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
244


